NASDAQ: ATYR - aTyr Pharma, Inc.

Rentabilität für sechs Monate: +77.84%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan aTyr Pharma, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen aTyr Pharma, Inc.

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

weitere details
The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2015-05-07
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.atyrpharma.com
Цена ао 3.24
Preisänderung pro Tag: -3.99% (3.26)
Preisänderung pro Woche: -14.95% (3.68)
Preisänderung pro Monat: -19.12% (3.87)
Preisänderung über 3 Monate: -16.31% (3.74)
Preisänderung über sechs Monate: +77.84% (1.76)
Preisänderung seit Jahresbeginn: -6.57% (3.35)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 1143.94 1
P/BV 3.85 4
P/E 0 0
EV/EBITDA -4.08 0
Gesamt: 3.25

Effizienz

Name Bedeutung Grad
ROA, % -58.88 0
ROE, % -79.69 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.2001 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -97.76 0
Rentabilität Ebitda, % 353.22 10
Rentabilität EPS, % -41.45 0
Gesamt: 6
Weitere Details

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
iShares Micro-Cap ETF 0.03199 17.09 1.54048
0.0317.091.54



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Sanjay S. Shukla M.D., M.S. President, CEO & Director 1972 (53 Jahr)
Ms. Jill M. Broadfoot Chief Financial Officer 1962 (63 Jahr)
Ms. Nancy E. Denyes Krueger General Counsel & Corporate Secretary 1968 (57 Jahre)
Xiang-Lei Yang Ph.D. Founder
Dr. Jayant Aphale MBA, Ph.D. Vice President of Technical Operations 1960 (65 Jahre)
Ms. Ashlee Dunston Director of Investor Relations & Corporate Communications
Mr. Peter Villiger Vice President of Corporate Development
Ms. Danielle Campbell VP of Human Resource
Dr. Leslie Nangle Ph.D. Vice President of Research
Dr. Ying J. Buechler Ph.D. Executive Director of Biologics Development & Manufacturing

Adresse: United States, San Diego, 10240 Sorrento Valley Road - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.atyrpharma.com